Neng-Wen Ke
Overview
Explore the profile of Neng-Wen Ke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
298
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou Y, Li L, Wang H, Huang H, Cao D, Ke N, et al.
Clin Nucl Med
. 2024 Apr;
49(6):516-520.
PMID: 38637950
Purpose: This study was designed to assess the uptake heterogeneity in neuroendocrine tumor (NET) patients at initial diagnosis with dual-tracer PET imaging and the staging changes and prognostic value it...
2.
Ren S, Tan Q, Cao D, Ke N, Liu X, Wang X
Eur J Radiol
. 2023 Mar;
162:110772.
PMID: 36940547
Purpose: To define the prognostic role of lymph node involvement (LNI) in patients with pancreatic neuroendocrine tumors (PNETs) and identify predictors of LNI using a comprehensive multifactor analysis focusing on...
3.
Wang M, Liu H, Ke N, Wu G, Chen S, Wang Y
J Mater Chem B
. 2023 Mar;
11(14):3164-3175.
PMID: 36938684
For typical biodegradable polymers, their overall performance almost declines exponentially to the degradation degree, which inevitably leads to a dilemma between the requirements of service life and retention time in...
4.
Shen X, Wang X, Zheng Z, Chen Y, Tan C, Liu X, et al.
Cancer Med
. 2023 Mar;
12(9):10438-10448.
PMID: 36938648
Objectives: Both cachexia and sarcopenia have been considered adverse predictors for prognosis in patients with pancreatic cancer; although sarcopenia and cachexia share some similarities, they are still defined as distinct...
5.
Ren S, Wang X, Ke N, Tan Q, Yang F, Yao W, et al.
Asian J Surg
. 2022 Jul;
46(2):774-779.
PMID: 35850904
Background: Pancreatic neuroendocrine tumors (pNETs) are heterogenous neoplasms, of which the prognosis varies widely. Purely cystic pancreatic neuroendocrine tumors (C-pNETs) are a small subset of pNETs in which data are...
6.
Wang X, Qiu J, Tan C, Chen Y, Tan Q, Ren S, et al.
Front Oncol
. 2022 Apr;
12:843376.
PMID: 35433485
Backgroud: Tumor grade is the determinant of the biological aggressiveness of pancreatic neuroendocrine tumors (PNETs) and the best current tool to help establish individualized therapeutic strategies. A noninvasive way to...
7.
Mou Y, Wang Z, Tan C, Chen Y, Liu X, Ke N
Front Oncol
. 2022 Mar;
12:838103.
PMID: 35350567
Background: Liver metastases (LMs) are common in advanced pancreatic neuroendocrine tumor (PNET) patients. Currently, the benefit of primary tumor resection (PTR) in the setting of PNET patients with liver metastases...
8.
Mou Y, Song Y, Chen H, Wang X, Huang W, Liu X, et al.
Front Surg
. 2022 Feb;
8:798867.
PMID: 35187048
Background: Surgery is an effective choice for the treatment of chronic pancreatitis (CP). However, there is no clear consensus regarding the best choice among the surgical procedures. The aim of...
9.
Yang M, Zeng L, Yao W, Ke N, Tan C, Tian B, et al.
Medicine (Baltimore)
. 2020 Nov;
99(46):e22291.
PMID: 33181635
Histologically, the World Health Organization has classified pancreatic neuroendocrine neoplasms (p-NENs) into well-differentiated pancreatic neuroendocrine tumors (G1/G2 p-NETs) and poorly-differentiated pancreatic neuroendocrine carcinoma (G3 p-NECs) based on tumor mitotic counts...
10.
Yang M, Zeng L, Hou S, Ke N, Tian B, Liu X, et al.
J Oncol
. 2020 Oct;
2020:6572398.
PMID: 33014053
Method: Data of patients who were surgically treated and clinicopathologically diagnosed as (MH)-NENs secondary to (GEP)-NENs at West China Hospital of Sichuan University from January 2006 to December 2018 were...